Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 5/20 | 0.69 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.57 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.57 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7165979 | 0.89 | PKM (0.63) | AKR1C3AKR1C2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7160777 | 0.83 | CAMK2A (0.55) | AKR1C3AKR1C2MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL7164948 | 0.82 | CXCL8 (0.59) | AKR1C3AKR1C2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL341539 | 0.81 | FABP3 (0.59) | AKR1C3AKR1C2MAPTSMN1; SMN2AKR1B10 | |
| SCHEMBL2436193 | 0.80 | CYP1A2 (0.63) | AKR1C3AKR1C2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4014665 | 0.80 | CYP1A2 (0.63) | AKR1C3AKR1C2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7164914 | 0.79 | GAA (0.64) | MAPTSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL6179431 | 0.79 | AKR1C3 (0.74) | AKR1C3AKR1C2MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7164974 | 0.78 | CXCL8 (0.70) | AKR1C3AKR1C2MAPK1AKR1B10KMT2A | |
| SCHEMBL9094091 | 0.77 | AKR1C3 (0.82) | AKR1C3AKR1C2MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552077-B2 | Kidney disorders | EXOCELL, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1242069-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6355680-B1 | BLOCKING REACTION OF GLUCOSE AND ALBUMIN | EXOCELL, INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | EXOCELL, INC. | 2001-10-25 | — | — | US | disclosed |
| WO-2001003684-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | ALB, AGER, TTR | AKR1C3 1185/4885AKR1C2 1104/4885MAPT 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.